Revvity unveils next-gen preclinical imaging technologies for breakthrough discoveries


Revvity, a US-based life sciences and diagnostics company, has expanded its imaging portfolio with the addition of next-generation preclinical imaging technologies to help researchers develop breakthrough discoveries.

The new products include the next-generation IVIS Spectrum 2 and the IVIS SpectrumCT 2 imaging systems, the Quantum GX3 microCT imaging solution, and the Vega preclinical ultrasound system.

The IVIS Spectrum 2 platform enables real-time and non-invasive longitudinal disease tracking, analysis of cell movement, assessment of drug safety, evaluation of treatment efficacy, and exploration of biological processes at the molecular level.

It comes with an advanced camera with eXcelon coating for high sensitivity imaging and a posing station that allows high-throughput imaging and enhanced workflow.

IVIS Spectrum 2 also combines 2D optical and full 3D imaging for simultaneous imaging of up to 10 specimens, Revvity said.

The IVIS SpectrumCT 2 system is said to integrate all the features of the IVIS Spectrum 2 along with integrated, low-dose CT, combining functional and anatomical imaging into a single device for maximum ease and flexibility.

The Quantum GX3 microCT system is said to be a high-resolution structural imaging solution built for enhanced image quality and versatility. It has updated five-micron spatial resolution, step-scanning, active ring reduction, and improved gating.

According to the diagnostics company, the Quantum GX3 has an 8mm to 86mm field of views to image a wide range of specimens from ex vivo biological samples.

The Vega solution is claimed as a hands-free, automated preclinical ultrasound imaging system. It is intended to swiftly provide 2D and 3D images for in vivo ultrasound studies within minutes.

Vega has an automated transducer and widefield imaging to help accelerate non-invasive research and drug development in areas such as oncology, liver, kidney disease, and cardiology.

Revvity life sciences SVP Alan Fletcher said: “In a time when innovative technologies steer medical advancements, we are committed to delivering versatile, high-throughput solutions that enhance preclinical R&D productivity.

“Our growing portfolio equips researchers with robust capabilities to illuminate scientific discoveries and can expedite the journey from discovery to cure.”